Drug Profile
Epstein-Barr virus vaccine - GlaxoSmithKline/MedImmune Vaccines
Alternative Names: 268664; EBV gp350 - Henogen; EBV vaccine 268664 - GlaxoSmithKline; GSK Biologicals' EBV vaccine (268664); GSK-268664; HENO 4; Recombinant gp350 vaccine for infectious mononucleosis - GlaxoSmithKlineLatest Information Update: 18 Aug 2015
Price :
$50
*
At a glance
- Originator MedImmune Vaccines
- Class Viral vaccines
- Mechanism of Action Immunostimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Discontinued Epstein-Barr virus infections; Infectious mononucleosis; Post-transplant lymphoproliferative disorder
Most Recent Events
- 20 Apr 2011 Epstein-Barr virus vaccine is still in phase II development
- 06 Jul 2009 Henogen has been acquired by Novasep
- 27 May 2009 EBV vaccine is still in phase II development trials for Epstein-Barr virus infections in Belgium